TY - JOUR
T1 - Enhancement of transfection efficiency through rapid and noncovalent post-PEGylation of poly(dimethylaminoethyl methacrylate)/DNA complexes
AU - Pirotton, Sabine
AU - Muller, Caroline
AU - Pantoustier, Nadège
AU - Botteman, François
AU - Collinet, Sébastien
AU - Grandfils, Christian
AU - Dandrifosse, Guy
AU - Degée, Philippe
AU - Dubois, Philippe
AU - Raes, Martine
PY - 2004/8
Y1 - 2004/8
N2 - Purpose. The aim of this work was to develop a new strategy to intro- duce poly(ethylene glycol) (PEG) into methacrylate-based polymer/DNA complexes in order to produce hemocompatible particles able to transfect cells in the presence of serum. Methods. Atom transfer radical polymerization was used to synthesize a well-defined poly(2-(dimethylamino)ethyl methacrylate) homopolymer (PDMAEMA) and a poly(2-(dimethylamino)ethyl methacrylate-b-poly(ethylene glycol) α-methyl ether, ω-methacrylate) palm-tree-like copolymer (P(DMAEMA-b-MAPEG)). The complexes obtained by self assembly of the pCMVβ plasmid and the polymers were used to transfect Cos-7 cells. Their physical properties - particle size and zeta potential - were characterized respectively by dynamic light scattering and electrophoretic mobility measurements. Ex vivo hemocompatibility was also determined. Results. The PDMAEMA/pCMVβ complexes transfected Cos-7 cells exclusively in the absence of serum. Although the P(DMAEMA-b-MAPEG) copolymer had no transfection activity per se, the addition of the latter to pre-formed PDMAEMA/DNA complexes significantly enhanced the activity and allowed transfection even in the presence of serum. The presence of palm-tree-like copolymers also improved the hemocompatibility properties of the complexes. No effect on platelet counts was observed for P(DMAEMA-b-MAPEG)/ pCMVβ complexes, whereas a decrease of platelets was clearly observed when blood cells were incubated with PDMAEMA/pCMVβ complexes. Conclusions. Such a synergistic effect of noncovalent PEGylation of poly(amino methacrylate)/DNA complexes allows a new and versatile approach to tune up transfection efficiency.
AB - Purpose. The aim of this work was to develop a new strategy to intro- duce poly(ethylene glycol) (PEG) into methacrylate-based polymer/DNA complexes in order to produce hemocompatible particles able to transfect cells in the presence of serum. Methods. Atom transfer radical polymerization was used to synthesize a well-defined poly(2-(dimethylamino)ethyl methacrylate) homopolymer (PDMAEMA) and a poly(2-(dimethylamino)ethyl methacrylate-b-poly(ethylene glycol) α-methyl ether, ω-methacrylate) palm-tree-like copolymer (P(DMAEMA-b-MAPEG)). The complexes obtained by self assembly of the pCMVβ plasmid and the polymers were used to transfect Cos-7 cells. Their physical properties - particle size and zeta potential - were characterized respectively by dynamic light scattering and electrophoretic mobility measurements. Ex vivo hemocompatibility was also determined. Results. The PDMAEMA/pCMVβ complexes transfected Cos-7 cells exclusively in the absence of serum. Although the P(DMAEMA-b-MAPEG) copolymer had no transfection activity per se, the addition of the latter to pre-formed PDMAEMA/DNA complexes significantly enhanced the activity and allowed transfection even in the presence of serum. The presence of palm-tree-like copolymers also improved the hemocompatibility properties of the complexes. No effect on platelet counts was observed for P(DMAEMA-b-MAPEG)/ pCMVβ complexes, whereas a decrease of platelets was clearly observed when blood cells were incubated with PDMAEMA/pCMVβ complexes. Conclusions. Such a synergistic effect of noncovalent PEGylation of poly(amino methacrylate)/DNA complexes allows a new and versatile approach to tune up transfection efficiency.
KW - atom transfer radical polymerization
KW - gene delivery
KW - pegylation
KW - transfection
UR - http://www.scopus.com/inward/record.url?scp=4344594697&partnerID=8YFLogxK
U2 - 10.1023/B:PHAM.0000036923.25772.97
DO - 10.1023/B:PHAM.0000036923.25772.97
M3 - Article
C2 - 15359584
VL - 21
SP - 1471
EP - 1479
JO - Pharmaceutical Research
JF - Pharmaceutical Research
IS - 8
ER -